Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.61 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8032994 | 0.88 | AOC3 (0.49) | AOC3ITGB3ITGA2B | |
| SCHEMBL22713754 | 0.87 | AOC3 (0.60) | AOC3ITGB3ITGA2BPRMT5WDR77 | |
| SCHEMBL29505381 | 0.86 | AOC3 (0.60) | AOC3PIN1PIN4ITGB3ITGA2B | |
| SCHEMBL14061622 | 0.86 | AOC3 (0.60) | AOC3PIN1PIN4ITGB3ITGA2B | |
| SCHEMBL6833682 | 0.85 | AOC3 (0.68) | AOC3ITGB3ITGA2BPRMT5WDR77 | |
| SCHEMBL8467965 | 0.85 | AOC3 (0.59) | AOC3PIN1PIN4ITGB3ITGA2B | |
| SCHEMBL4070429 | 0.83 | AOC3 (0.56) | AOC3PIN1PIN4ALOX15 | |
| SCHEMBL14062095 | 0.82 | AOC3 (0.59) | AOC3ITGB3ITGA2B | |
| SCHEMBL7796015 | 0.81 | ITGB3 (0.60) | ITGB3ITGA2B | |
| SCHEMBL29438592 | 0.81 | PRMT5 (0.48) | ITGB3ITGA2BPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| CN-109988109-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof | 广东东阳光药业有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20200377461-A1 | AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-12-03 | — | — | US | disclosed |
| US-20040058915-A1 | Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists | PHARMACIA CORPORATION | 2004-03-25 | — | — | US | disclosed |
| US-20020072518-A1 | For therapy tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy | PHARMACIA CORPORATION | 2002-06-13 | — | — | US | disclosed |
| EP-0869787-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| CN-1209060-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-02-24 | — | — | CN | disclosed |
| CN-1209063-A | Vitronection receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-02-24 | — | — | CN | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072518-A1 | For therapy tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy | ITGB1, ITGB5, ITGB3 | AOC3 2748/4885PIN1 4591/4885PIN4 4749/4885 |
| US-20040058915-A1 | Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists | ITGB5, ITGB3, ITGAV | AOC3 2547/4885PIN1 4285/4885PIN4 4678/4885 |
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | VCAM1, VAPB, ICAM1 | AOC3 6/4885PIN1 3460/4885PIN4 1810/4885 |
| US-20200377461-A1 | AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF | VCAM1, VAPB, ICAM1 | AOC3 6/4885PIN1 3460/4885PIN4 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.